
50 High Dividend Yield Stocks as of 2nd January 2025
On the domestic front, the market will closely monitor developments towards the upcoming budget and the rate cut trajectory in the Indian market. We anticipate one to two rate cuts from the RBI in 2025, contingent upon inflation trends and the broader growth dynamics. These events are expected to keep the Indian equity market volatile, and it could respond in either direction based on the developments.
Given the attractive growth potential for domestic tourism industry and strong company financials, ITC Hotels has a long runway to capture the growth opportunities in the tourism industry. Investors can participate in the growth story of ITC’s hotel business by purchasing a minimum of 10 ITC shares on or before 03rd January, 2025. The average EV/EBITDA multiple of its industry peers (Indian Hotels & EIH Ltd) is 25.0x. Assuming that ITC Hotels will list at an EV/EBITDA multiple of 20.0x-30.0x, the share price of ITC Hotels Ltd is expected to list in the range of Rs 113 to Rs 170 per share
Lumax Auto Technologies Ltd (LATL) is one of India’s leading auto component manufacturers specialising in components such as head and tail lamps, air intake systems, plastic tanks, door panels, switches, sensors, actuators, antennas, gear shifter, two-wheeler frames, seating structures, swing arms and other aftermarket products
We continue to believe in the long-term growth story of the Indian equity market. However, with current valuations offering limited scope for further expansion, an increase in corporate earnings will be the primary driver of the market returns moving forward. Hence, bottom-up stock picking with a focus on ‘Growth at a Reasonable Price’ and ‘Quality’ would be keys to generating satisfactory returns in the next one year. We also suggest a “Buy on Dips” strategy in the stocks listed below with an investment horizon of over 12 months
PNBHF is pivoting its product mix toward the emerging and affordable housing segments, with both these relatively higher-yielding segments now contributing ~23% to the loan mix (compared to ~18% as of Mar’23). This pivot will gradually help the company secure a structural improvement in its blended yields and eventually deliver an expansion in its NIM profile.
PPL owns 17 development and manufacturing facilities across India, US and UK with capabilities in sterile, API, formulations, drug discovery and manufacturing of nutrition products. The company holds 49% stake in AbbVie Therapeutics, JV with Allergan, and 33.33% in Yapan Bio which operates in the biologics / bio-therapeutics and vaccine segments
Hiren Ved stated in his latest interview to CNBC TV18 that he has no Banking stocks in his portfolio because Banks are suffering a double whammy. On the one hand, they are unable to get cheap deposits from customers by way of FDs. At the same time, the RBI has imposed restrictions on their ability to give unsecured loans which was a highly profitable activity.
EvoLve theme by Theme4Press • Powered by WordPress & Rakesh Jhunjhunwala Rakesh Jhunjhunwala
Fan Site: Inspired, Not Endorsed, By Rakesh Jhunjhunwala
Recent Comments